Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022
Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and categor...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2024-04, Vol.38 (4), p.315-327 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 327 |
|---|---|
| container_issue | 4 |
| container_start_page | 315 |
| container_title | Annals of nuclear medicine |
| container_volume | 38 |
| creator | Okizaki, Atsutaka Nishiyama, Yoshihiro Inui, Yoshitaka Otsuka, Hideki Takanami, Kentaro Nakajo, Masatoyo Nakatani, Koya Nogami, Munenobu Hirata, Kenji Maeda, Yukito Yoshimura, Mana Wakabayashi, Hiroshi |
| description | Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data. A total of 1095 institutes responded to the survey, including 364 positron emission tomography (PET) centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1299 in total, with 2.5% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 83.8% and 35.5%, respectively. The number of single-photon tracer studies in 2022 was 1.11 million which means increase in 2.7% in 5 years. Bone scintigraphy was a leading examination (31.0%), followed by myocardial scintigraphy (27.1%) and cerebral perfusion study (23.8%) in order. The percentage of SPECT studies showed an increase from 63.5% in previous survey to 66.8% in this survey. PET centers have also increased from 389 to 412, as compared with the previous one. One hundred and twenty-two PET centers have installed one or two in-house cyclotrons. Increasing trends of the PET studies were observed from 1992 to 2017, the trend changed and PET studies showed 1.5% decrease in 5 years.
18
F-FDG accounted for 98.6% (610,497 examinations). PET examinations using
11
C-methionine,
13
N-NH
3
and
11
C-PIB have decreased, with 1624, 2146 and 525 examinations, respectively in 2022. The total number of nuclear medicine examination was eventually increased by 1.0%. Therapies for pheochromocytoma or paraganglioma (PPGL) with
131
I-MIBG and for neuroendocrine tumor with
177
Lu-DOTA-TATE were newly started, however, a total number of targeted radionuclide therapy was decreased by 17.7% because
131
I-radioiodine and
223
Ra targeted therapies were decreased and supply of some radioisotopes was discontinued.
131
I-radioiodine targeted therapy showed a decrease in 5 years (− 15.9%), including 4099 patients for thyroid cancer. The number of out-patient thyroid bed ablation therapy with 1110 MBq of
131
I was also decreased to 1015 per year. The number of admission rooms specialized for radionuclide targeted therapy increased from 157 to 160. The number of
223
Ra targete |
| doi_str_mv | 10.1007/s12149-024-01905-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2933461014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2972725780</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-a08043abd80d134233bc94675a07e08bc0bd42e80131531a11dd2da47c7b72173</originalsourceid><addsrcrecordid>eNp9kD1PHDEQhq0oiDsIfyBFZClNmoWZsffsTRchwocQFITa8np9OaM778beBfHvMRxJJAqqKeZ53xk9jH1GOEQAdZSRUDYVkKwAG6ir5gObo17IaiGF-Mjm0KCsFGo1Y3s53wGQrjXtspnQkrDGes5uria39jbxje-CC9HzIVk3Bud5iPzCDjZ-55YnP_Rp5P2SjyvPY4jjikc7hj4-hM7zPKV7__icICD6xHaWdp39wevcZ7c_T34dn1WX16fnxz8uKycaGisLGqSwbaehQyFJiNY1cqFqC8qDbh20nSSvAQXWAi1i11FnpXKqVYRK7LNv294h9X8mn0ezCdn59dpG30_ZUCOEXCCgLOjXN-hdP6VYviuUIkW10lAo2lIu9TknvzRDChubHg2CeVZutspNUW5elJumhL68Vk9tkfgv8tdxAcQWyGUVf_v0__Y7tU9Gu4kZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2972725780</pqid></control><display><type>article</type><title>Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022</title><source>Springer Nature - Complete Springer Journals</source><creator>Okizaki, Atsutaka ; Nishiyama, Yoshihiro ; Inui, Yoshitaka ; Otsuka, Hideki ; Takanami, Kentaro ; Nakajo, Masatoyo ; Nakatani, Koya ; Nogami, Munenobu ; Hirata, Kenji ; Maeda, Yukito ; Yoshimura, Mana ; Wakabayashi, Hiroshi</creator><creatorcontrib>Okizaki, Atsutaka ; Nishiyama, Yoshihiro ; Inui, Yoshitaka ; Otsuka, Hideki ; Takanami, Kentaro ; Nakajo, Masatoyo ; Nakatani, Koya ; Nogami, Munenobu ; Hirata, Kenji ; Maeda, Yukito ; Yoshimura, Mana ; Wakabayashi, Hiroshi</creatorcontrib><description>Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data. A total of 1095 institutes responded to the survey, including 364 positron emission tomography (PET) centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1299 in total, with 2.5% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 83.8% and 35.5%, respectively. The number of single-photon tracer studies in 2022 was 1.11 million which means increase in 2.7% in 5 years. Bone scintigraphy was a leading examination (31.0%), followed by myocardial scintigraphy (27.1%) and cerebral perfusion study (23.8%) in order. The percentage of SPECT studies showed an increase from 63.5% in previous survey to 66.8% in this survey. PET centers have also increased from 389 to 412, as compared with the previous one. One hundred and twenty-two PET centers have installed one or two in-house cyclotrons. Increasing trends of the PET studies were observed from 1992 to 2017, the trend changed and PET studies showed 1.5% decrease in 5 years.
18
F-FDG accounted for 98.6% (610,497 examinations). PET examinations using
11
C-methionine,
13
N-NH
3
and
11
C-PIB have decreased, with 1624, 2146 and 525 examinations, respectively in 2022. The total number of nuclear medicine examination was eventually increased by 1.0%. Therapies for pheochromocytoma or paraganglioma (PPGL) with
131
I-MIBG and for neuroendocrine tumor with
177
Lu-DOTA-TATE were newly started, however, a total number of targeted radionuclide therapy was decreased by 17.7% because
131
I-radioiodine and
223
Ra targeted therapies were decreased and supply of some radioisotopes was discontinued.
131
I-radioiodine targeted therapy showed a decrease in 5 years (− 15.9%), including 4099 patients for thyroid cancer. The number of out-patient thyroid bed ablation therapy with 1110 MBq of
131
I was also decreased to 1015 per year. The number of admission rooms specialized for radionuclide targeted therapy increased from 157 to 160. The number of
223
Ra targeted therapies for castration-resistant metastatic prostate cancer (mCRPC) was 1041 patients. This survey was performed during COVID-19 pandemic, however, total number of nuclear medicine examinations was almost same as previous survey (+ 1.0%). Radionuclide therapies with
131
I-MIBG and
177
Lu-DOTA-TATE were newly started, and new radionuclide therapy will be available in future, therefore, the development of radionuclide therapy will be continued. We are convinced that this survey report is useful in understanding the current status of the nuclear medicine practice in Japan, and in devising the new strategy to strengthen a role of nuclear medicine.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-024-01905-9</identifier><identifier>PMID: 38421515</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Ablation ; Ammonia ; Cameras ; Castration ; Computed tomography ; COVID-19 ; Cyclotrons ; Imaging ; Iodine 131 ; Iodine isotopes ; Lutetium isotopes ; Medicine ; Medicine & Public Health ; Metastases ; Methionine ; Neuroendocrine tumors ; Nuclear Medicine ; Others ; Paraganglioma ; Pheochromocytoma ; Positron emission ; Positron emission tomography ; Prostate cancer ; Radiation therapy ; Radioisotopes ; Radiology ; Scintigraphy ; Single photon emission computed tomography ; Surveys ; Thyroid cancer ; Thyroid gland</subject><ispartof>Annals of nuclear medicine, 2024-04, Vol.38 (4), p.315-327</ispartof><rights>The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c392t-a08043abd80d134233bc94675a07e08bc0bd42e80131531a11dd2da47c7b72173</cites><orcidid>0000-0001-8203-827X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-024-01905-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-024-01905-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38421515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Okizaki, Atsutaka</creatorcontrib><creatorcontrib>Nishiyama, Yoshihiro</creatorcontrib><creatorcontrib>Inui, Yoshitaka</creatorcontrib><creatorcontrib>Otsuka, Hideki</creatorcontrib><creatorcontrib>Takanami, Kentaro</creatorcontrib><creatorcontrib>Nakajo, Masatoyo</creatorcontrib><creatorcontrib>Nakatani, Koya</creatorcontrib><creatorcontrib>Nogami, Munenobu</creatorcontrib><creatorcontrib>Hirata, Kenji</creatorcontrib><creatorcontrib>Maeda, Yukito</creatorcontrib><creatorcontrib>Yoshimura, Mana</creatorcontrib><creatorcontrib>Wakabayashi, Hiroshi</creatorcontrib><title>Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data. A total of 1095 institutes responded to the survey, including 364 positron emission tomography (PET) centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1299 in total, with 2.5% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 83.8% and 35.5%, respectively. The number of single-photon tracer studies in 2022 was 1.11 million which means increase in 2.7% in 5 years. Bone scintigraphy was a leading examination (31.0%), followed by myocardial scintigraphy (27.1%) and cerebral perfusion study (23.8%) in order. The percentage of SPECT studies showed an increase from 63.5% in previous survey to 66.8% in this survey. PET centers have also increased from 389 to 412, as compared with the previous one. One hundred and twenty-two PET centers have installed one or two in-house cyclotrons. Increasing trends of the PET studies were observed from 1992 to 2017, the trend changed and PET studies showed 1.5% decrease in 5 years.
18
F-FDG accounted for 98.6% (610,497 examinations). PET examinations using
11
C-methionine,
13
N-NH
3
and
11
C-PIB have decreased, with 1624, 2146 and 525 examinations, respectively in 2022. The total number of nuclear medicine examination was eventually increased by 1.0%. Therapies for pheochromocytoma or paraganglioma (PPGL) with
131
I-MIBG and for neuroendocrine tumor with
177
Lu-DOTA-TATE were newly started, however, a total number of targeted radionuclide therapy was decreased by 17.7% because
131
I-radioiodine and
223
Ra targeted therapies were decreased and supply of some radioisotopes was discontinued.
131
I-radioiodine targeted therapy showed a decrease in 5 years (− 15.9%), including 4099 patients for thyroid cancer. The number of out-patient thyroid bed ablation therapy with 1110 MBq of
131
I was also decreased to 1015 per year. The number of admission rooms specialized for radionuclide targeted therapy increased from 157 to 160. The number of
223
Ra targeted therapies for castration-resistant metastatic prostate cancer (mCRPC) was 1041 patients. This survey was performed during COVID-19 pandemic, however, total number of nuclear medicine examinations was almost same as previous survey (+ 1.0%). Radionuclide therapies with
131
I-MIBG and
177
Lu-DOTA-TATE were newly started, and new radionuclide therapy will be available in future, therefore, the development of radionuclide therapy will be continued. We are convinced that this survey report is useful in understanding the current status of the nuclear medicine practice in Japan, and in devising the new strategy to strengthen a role of nuclear medicine.</description><subject>Ablation</subject><subject>Ammonia</subject><subject>Cameras</subject><subject>Castration</subject><subject>Computed tomography</subject><subject>COVID-19</subject><subject>Cyclotrons</subject><subject>Imaging</subject><subject>Iodine 131</subject><subject>Iodine isotopes</subject><subject>Lutetium isotopes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Methionine</subject><subject>Neuroendocrine tumors</subject><subject>Nuclear Medicine</subject><subject>Others</subject><subject>Paraganglioma</subject><subject>Pheochromocytoma</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Radiation therapy</subject><subject>Radioisotopes</subject><subject>Radiology</subject><subject>Scintigraphy</subject><subject>Single photon emission computed tomography</subject><subject>Surveys</subject><subject>Thyroid cancer</subject><subject>Thyroid gland</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PHDEQhq0oiDsIfyBFZClNmoWZsffsTRchwocQFITa8np9OaM778beBfHvMRxJJAqqKeZ53xk9jH1GOEQAdZSRUDYVkKwAG6ir5gObo17IaiGF-Mjm0KCsFGo1Y3s53wGQrjXtspnQkrDGes5uria39jbxje-CC9HzIVk3Bud5iPzCDjZ-55YnP_Rp5P2SjyvPY4jjikc7hj4-hM7zPKV7__icICD6xHaWdp39wevcZ7c_T34dn1WX16fnxz8uKycaGisLGqSwbaehQyFJiNY1cqFqC8qDbh20nSSvAQXWAi1i11FnpXKqVYRK7LNv294h9X8mn0ezCdn59dpG30_ZUCOEXCCgLOjXN-hdP6VYviuUIkW10lAo2lIu9TknvzRDChubHg2CeVZutspNUW5elJumhL68Vk9tkfgv8tdxAcQWyGUVf_v0__Y7tU9Gu4kZ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Okizaki, Atsutaka</creator><creator>Nishiyama, Yoshihiro</creator><creator>Inui, Yoshitaka</creator><creator>Otsuka, Hideki</creator><creator>Takanami, Kentaro</creator><creator>Nakajo, Masatoyo</creator><creator>Nakatani, Koya</creator><creator>Nogami, Munenobu</creator><creator>Hirata, Kenji</creator><creator>Maeda, Yukito</creator><creator>Yoshimura, Mana</creator><creator>Wakabayashi, Hiroshi</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8203-827X</orcidid></search><sort><creationdate>20240401</creationdate><title>Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022</title><author>Okizaki, Atsutaka ; Nishiyama, Yoshihiro ; Inui, Yoshitaka ; Otsuka, Hideki ; Takanami, Kentaro ; Nakajo, Masatoyo ; Nakatani, Koya ; Nogami, Munenobu ; Hirata, Kenji ; Maeda, Yukito ; Yoshimura, Mana ; Wakabayashi, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-a08043abd80d134233bc94675a07e08bc0bd42e80131531a11dd2da47c7b72173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Ablation</topic><topic>Ammonia</topic><topic>Cameras</topic><topic>Castration</topic><topic>Computed tomography</topic><topic>COVID-19</topic><topic>Cyclotrons</topic><topic>Imaging</topic><topic>Iodine 131</topic><topic>Iodine isotopes</topic><topic>Lutetium isotopes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Methionine</topic><topic>Neuroendocrine tumors</topic><topic>Nuclear Medicine</topic><topic>Others</topic><topic>Paraganglioma</topic><topic>Pheochromocytoma</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Radiation therapy</topic><topic>Radioisotopes</topic><topic>Radiology</topic><topic>Scintigraphy</topic><topic>Single photon emission computed tomography</topic><topic>Surveys</topic><topic>Thyroid cancer</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okizaki, Atsutaka</creatorcontrib><creatorcontrib>Nishiyama, Yoshihiro</creatorcontrib><creatorcontrib>Inui, Yoshitaka</creatorcontrib><creatorcontrib>Otsuka, Hideki</creatorcontrib><creatorcontrib>Takanami, Kentaro</creatorcontrib><creatorcontrib>Nakajo, Masatoyo</creatorcontrib><creatorcontrib>Nakatani, Koya</creatorcontrib><creatorcontrib>Nogami, Munenobu</creatorcontrib><creatorcontrib>Hirata, Kenji</creatorcontrib><creatorcontrib>Maeda, Yukito</creatorcontrib><creatorcontrib>Yoshimura, Mana</creatorcontrib><creatorcontrib>Wakabayashi, Hiroshi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okizaki, Atsutaka</au><au>Nishiyama, Yoshihiro</au><au>Inui, Yoshitaka</au><au>Otsuka, Hideki</au><au>Takanami, Kentaro</au><au>Nakajo, Masatoyo</au><au>Nakatani, Koya</au><au>Nogami, Munenobu</au><au>Hirata, Kenji</au><au>Maeda, Yukito</au><au>Yoshimura, Mana</au><au>Wakabayashi, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>38</volume><issue>4</issue><spage>315</spage><epage>327</epage><pages>315-327</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every 5 years since 1982 to survey contemporary nuclear medicine practice and its changes over the years. The subcommittee sent questionnaires, including the number and category of examinations as well as the kind of the radiopharmaceuticals during the 30 days of June 2022 to all nuclear medicine institutes in Japan. The total numbers of them for the year 2022 were estimated depends on the 1-month data. A total of 1095 institutes responded to the survey, including 364 positron emission tomography (PET) centers. The recovery rate was 90.6%. The number of gamma cameras installed was 1299 in total, with 2.5% decrease in 5 years. Dual-head cameras and hybrid SPECT/CT scanners accounted for 83.8% and 35.5%, respectively. The number of single-photon tracer studies in 2022 was 1.11 million which means increase in 2.7% in 5 years. Bone scintigraphy was a leading examination (31.0%), followed by myocardial scintigraphy (27.1%) and cerebral perfusion study (23.8%) in order. The percentage of SPECT studies showed an increase from 63.5% in previous survey to 66.8% in this survey. PET centers have also increased from 389 to 412, as compared with the previous one. One hundred and twenty-two PET centers have installed one or two in-house cyclotrons. Increasing trends of the PET studies were observed from 1992 to 2017, the trend changed and PET studies showed 1.5% decrease in 5 years.
18
F-FDG accounted for 98.6% (610,497 examinations). PET examinations using
11
C-methionine,
13
N-NH
3
and
11
C-PIB have decreased, with 1624, 2146 and 525 examinations, respectively in 2022. The total number of nuclear medicine examination was eventually increased by 1.0%. Therapies for pheochromocytoma or paraganglioma (PPGL) with
131
I-MIBG and for neuroendocrine tumor with
177
Lu-DOTA-TATE were newly started, however, a total number of targeted radionuclide therapy was decreased by 17.7% because
131
I-radioiodine and
223
Ra targeted therapies were decreased and supply of some radioisotopes was discontinued.
131
I-radioiodine targeted therapy showed a decrease in 5 years (− 15.9%), including 4099 patients for thyroid cancer. The number of out-patient thyroid bed ablation therapy with 1110 MBq of
131
I was also decreased to 1015 per year. The number of admission rooms specialized for radionuclide targeted therapy increased from 157 to 160. The number of
223
Ra targeted therapies for castration-resistant metastatic prostate cancer (mCRPC) was 1041 patients. This survey was performed during COVID-19 pandemic, however, total number of nuclear medicine examinations was almost same as previous survey (+ 1.0%). Radionuclide therapies with
131
I-MIBG and
177
Lu-DOTA-TATE were newly started, and new radionuclide therapy will be available in future, therefore, the development of radionuclide therapy will be continued. We are convinced that this survey report is useful in understanding the current status of the nuclear medicine practice in Japan, and in devising the new strategy to strengthen a role of nuclear medicine.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38421515</pmid><doi>10.1007/s12149-024-01905-9</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-8203-827X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2024-04, Vol.38 (4), p.315-327 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2933461014 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Ablation Ammonia Cameras Castration Computed tomography COVID-19 Cyclotrons Imaging Iodine 131 Iodine isotopes Lutetium isotopes Medicine Medicine & Public Health Metastases Methionine Neuroendocrine tumors Nuclear Medicine Others Paraganglioma Pheochromocytoma Positron emission Positron emission tomography Prostate cancer Radiation therapy Radioisotopes Radiology Scintigraphy Single photon emission computed tomography Surveys Thyroid cancer Thyroid gland |
| title | Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T17%3A42%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nuclear%20medicine%20practice%20in%20Japan:%20a%20report%20of%20the%20ninth%20nationwide%20survey%20in%202022&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Okizaki,%20Atsutaka&rft.date=2024-04-01&rft.volume=38&rft.issue=4&rft.spage=315&rft.epage=327&rft.pages=315-327&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-024-01905-9&rft_dat=%3Cproquest_cross%3E2972725780%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2972725780&rft_id=info:pmid/38421515&rfr_iscdi=true |